Curcumin entrapped into lipid nanosystems inhibits neuroblastoma cancer cell growth and activates Hsp70 protein

Current Nanoscience

Volumn 6, Issue 5, 2010, Pages 439-445

  Bondi M L ^a   Craparo, E F ^b   Picone, P ^b,c   Di Carlo, M ^c   Di Gesu R ^b   Capuano, G ^b   Giammona, G ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Cancer; Curcumin; Drug release; Hsp70 protein; Human neuroblastoma cells; Nanostructured lipid carriers

Indexed keywords

BIOCHEMISTRY; CELL CULTURE; CELLS; CYTOLOGY; DISEASES; DRUG DOSAGE; NANOPARTICLES; PROTEINS;

CANCER; CURCUMIN; DRUG RELEASE; HUMAN NEUROBLASTOMA; NANOSTRUCTURED LIPID CARRIERS;

NANOSYSTEMS;

CURCUMIN; DRUG CARRIER; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; HEAT SHOCK PROTEIN 70; IMWITOR; LIPID; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL VIABILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PARTICLE SIZE; PH; PLASMA; PRIORITY JOURNAL; WESTERN BLOTTING; ZETA POTENTIAL;

ANIMALIA; CUMINUM CYMINUM;

EID: 77958490878     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341310797575005     Document Type: Article

References (38)

1. Sahu, A.; Bora, U.; Kasoju, N.; Goswami, P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocar-rier for curcumin delivery to cancer cells. Acta Biomater., 2008, 4, 1752-1761.
2. Sou, K.; Inenaga, S.; Takeoka, S.; Tsuchida, E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm., 2008, 352, 287-293.
3. Shishodia, S.; Sethi, G.; Aggarwal, B.B. Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci., 2005, 1056, 206-217.
4. Maheshwari, R.K.; Singh, A.K.; Gaddipati, J.; Srimal, R.C. Multiple biological activities of curcumin: a short review. Life Sci., 2006, 78, 2081-2087.
5. Duvoix, A.; Blasius, R.; Delhalle, S.; Schnekenburger, M.; Morceau, F.; Henry, E.; Dicato, M.; Diederich, M. Chemopreventive and therapeutic effects of curcumin. Cancer Lett., 2005, 223, 181-190.
6. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23, 363-398.
7. Wang, Z.; Zhang, Y.; Banerjee, S.; Li, Y.; Sarkar, F.H. Notch-1 down regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer, 2006, 106, 2503-2513.
8. Lev-Ari, S.; Zinger, H.; Kazanov, D.; Yona, D.; Ben-Yosef, R.; Starr, A.; Figer, A.; Arber, N. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother., 2005, 59(Suppl 2), S276-280.
9. Aggarwal, B.B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R.A.; Bueso-Ramos, C.E.; Price, J.E. Curcumin suppresses the paclitaxel induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 2005, 11, 7490-7498.
10. Khor, T.O.; Keum, Y.S.; Lin, W.; Kim, J.H.; Hu, R.; Shen, G.; Xu, C.; Gopalakrishnan, A.; Reddy, B.; Zheng, X.; Conney, A.H.; Kong, A.N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res., 2006, 66, 613-621.
11. Deeb, D.; Jiang, H.; Gao, X.; Hafner, M.S.; Wong, H.; Divine, G.; Chapman, R.A.; Dulchavsky, S.A.; Gautam, S.C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosisinducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phos-phorylation. Mol. Cancer Ther., 2004, 3, 803-812.
12. Sharma, R.A.; Gescher, A.J.; Steward, W.P. Curcumin: the story so far. Eur. J. Cancer, 2005, 41, 1955-1968.
13. Sharma, R.A.; Euden, S.A.; Platton, S.L.; Cooke, D.N.; Shafayat, A.; Hewitt, H.R.; Marczylo, T.H.; Morgan, B.; Hemingway, D.; Plummer, S.M.; Pirmo-hamed, M.; Gescher, A.J.; Steward, W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10, 6847-6854.
14. Bukau, B.; Horwich, A.L. The Hsp70 and Hsp60 chaperone machines. Cell, 1998, 92, 351-366.
15. Nylandsted, J.; Rohde, M.; Brand, K.; Bastholm, L.; Elling, F.; Jaattela, M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl. Acad. Sci. USA, 2000, 97, 7871-7876.
16. Jaattela, M. Escaping cell death: survival proteins in cancer. Exp. Cell Res., 1999, 248, 30-43.
17. Teiten, M.-H.; Teiten, M.H.; Reuter, S.; Schmucker, S.; Dicato, M.; Diederich, M. Induction of heat shock response by curcumin in human leukemia cells. Cancer Lett., 2009, 279, 145-154.
18. Chen, Y.C.; Tsai, S.H.; Shen, S.C.; Lin J.K.; Lee W.R. Alternative activation of extracellular signal-regulated protein kinases in curcumin and arsenite-induced HSP70 gene expression in human colorectal carcinoma cells. Eur. J. Cell Biol., 2001, 80, 213-221.
19. Chen, C.; Johnston, T.D.; Jeon, H.; Gedaly, R.; McHugh, P.P.; Burke, T.G.; Ranjan, D. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int. J. Pharm., 2009, 366, 133-139.
20. Lin, C.; Lin, H.; Chen, H.; Yu, M.; Lee, M. Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsion. Food Chem., 2009, 116, 923-928.
21. Musthaba, S.M.; Ahmad, S.; Ahuja, A.; Ali, J.; Baboota, S. Nano approaches to enhance pharmacokinetic and pharmacodinamic activity of plant origin drugs. Curr. Nanosci., 2009, 5, 344.
22. Letchford, K.; Liggins, R.; Burt, H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J. Pharm. Sci., 2008, 97, 1179-1190.
23. Li, L.; Ahmed, B.; Mehta, K.; Kurzrock, R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis and angiogenesis in co-lorectal cancer. Mol. Cancer Ther., 2007, 6, 1276-1282.
24. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol., 2007, 5, 3.
25. Doktorovova, S.; Gokce, E.; Ozyazici, M.; Souto, E.B. Lipid matrix nanoparticles: pharmacokinetics and biopharmaceutics. Curr. Nanosci., 2009, 5, 358.
26. Souto, E.B.; Müller, R.H. Lipid nanoparticles (SLN and NLC) for drug delivery. In: Nanoparticles for pharmaceutical applications (Domb, A.; To-bata, Y.; Kumar, R.; Farber, S. Eds.), American Scientific Publishers, California, 2007.
27. Almeida, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., 2007, 59, 478-490.
28. Müller, R.H.; Radtke, M.; Wissing, S.A. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers. In: Encyclopedia of Nanoscience and Nanotechnology (Nalwa, H.S. Ed.), American Scientific Publishers, California, 2004.
29. Mehnert, W.; Mader, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47, 165-196.
30. Belting, M.; Sandgren, S.; Wittrup, A. Nuclear delivery of macromolecules: barriers and carriers. Adv. Drug. Deliv. Rev., 2005, 57, 505-527.
31. Bondì, M.L.; Montana, G.; Craparo, E.F.; Picone, P.; Capuano, G.; Di Carlo, M.; Giammona, G. Ferulic acid-loaded lipid nanostructures as drug delivery systems for alzheimer's disease: preparation, characterization and cytotoxic-ity studies. Curr. Nanosci., 2009, 5, 26.
32. Bondì, M.L.; Azzolina, A.; Craparo, E.F.; Capuano, G.; Lampiasi, N.; Giammona, G.; Cervello, M. Solid lipid nanoparticles containing nimesulide: preparation, characterization and cytotoxicity studies. Curr. Nanosci., 2009, 5, 39.
33. Reuter, S.; Eifes, S.; Dicato, M.; Aggarwal, B.B.; Diederich, M. Modulation and anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol., 2008, 76, 1340-1351.
34. Bondì, M.L.; Craparo, E.F.; Cervello, M.; Azzolina, A.; Diana, P.; Martorana, A.; Cirrincione, G. Nanostructured Lipid Carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv., 2007, 14, 61-67.
35. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27, 4356-4373.
36. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41, 189-207.
37. Singh, R.; Lillard, Jr. J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-223.
38. Wang, Y.-J.; Pan, M.-H.; Cheng, A.-L.; Lin, L.-I.; Ho, Y.-S.; Hsieh, C.-Y.; Lin, J.-K. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal., 1997, 15, 1867-1876.